BioLineRx (BLRX) Cash & Current Investments (2021 - 2025)

BioLineRx has reported Cash & Current Investments over the past 5 years, most recently at $20.9 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $20.9 million for Q4 2025, up 6.72% from a year ago — trailing twelve months through Dec 2025 was $20.9 million (up 6.72% YoY), and the annual figure for FY2025 was $20.9 million, up 6.72%.
  • Cash & Current Investments for Q4 2025 was $20.9 million at BioLineRx, up from $19.6 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for BLRX hit a ceiling of $57.1 million in Q4 2021 and a floor of $19.6 million in Q4 2024.
  • Median Cash & Current Investments over the past 5 years was $43.0 million (2023), compared with a mean of $38.3 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 54.5% in 2024 and later increased 6.72% in 2025.
  • BioLineRx's Cash & Current Investments stood at $57.1 million in 2021, then fell by 10.59% to $51.1 million in 2022, then dropped by 15.83% to $43.0 million in 2023, then crashed by 54.5% to $19.6 million in 2024, then rose by 6.72% to $20.9 million in 2025.
  • The last three reported values for Cash & Current Investments were $20.9 million (Q4 2025), $19.6 million (Q4 2024), and $43.0 million (Q4 2023) per Business Quant data.